Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Castro

Showing results (151-160 of 194) with videos related to

Pageof 20
Sort By:
European Urology Oncology|July 17, 2019
Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer PatientsLucía Oliva, Rebeca Lozano, Casilda Llácer, et al.
Journal of Managed Care & Specialty Pharmacy|July 5, 2023
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defectsMatthew R Smith, Shahneen Sandhu, Daniel J George, et al.
JCO Precision Oncology|August 7, 2025
Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene AlterationsMihaela Aldea, Emeline Orillard, Alice Bernard-Tessier, et al.
European Urology|November 6, 2020
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based TreatmentVicenç Ruiz de Porras, Xieng C Wang, Luis Palomero, et al.
European Urology|March 8, 2020
Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate CancerDavid Lorente, Elena Castro, Rebeca Lozano, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2021
Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defectsMihaela Aldea, Laurent Lam, Emeline Orillard, et al.
The Prostate|September 13, 2021
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutationsAlexandra O Sokolova, Catherine H Marshall, Rebeca Lozano, et al.
Cancers|June 2, 2021
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) PatientsRebeca Lozano, David Lorente, Isabel M Aragon, et al.
Journal for Immunotherapy of Cancer|June 28, 2022
Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genesAnna Sofia Trigos, Anupama Pasam, Patricia Banks, et al.
Scientific Reports|June 25, 2013
Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk menEmma Killick, Richard Morgan, Francesca Launchbury, et al.
Pageof 20

Showing results (151-160 of 194) with videos related to

Sort By:
Pageof 20
European Urology Oncology|July 17, 2019
Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer PatientsLucía Oliva, Rebeca Lozano, Casilda Llácer, et al.
Journal of Managed Care & Specialty Pharmacy|July 5, 2023
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defectsMatthew R Smith, Shahneen Sandhu, Daniel J George, et al.
JCO Precision Oncology|August 7, 2025
Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene AlterationsMihaela Aldea, Emeline Orillard, Alice Bernard-Tessier, et al.
European Urology|November 6, 2020
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based TreatmentVicenç Ruiz de Porras, Xieng C Wang, Luis Palomero, et al.
European Urology|March 8, 2020
Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate CancerDavid Lorente, Elena Castro, Rebeca Lozano, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2021
Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defectsMihaela Aldea, Laurent Lam, Emeline Orillard, et al.
The Prostate|September 13, 2021
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutationsAlexandra O Sokolova, Catherine H Marshall, Rebeca Lozano, et al.
Cancers|June 2, 2021
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) PatientsRebeca Lozano, David Lorente, Isabel M Aragon, et al.
Journal for Immunotherapy of Cancer|June 28, 2022
Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genesAnna Sofia Trigos, Anupama Pasam, Patricia Banks, et al.
Scientific Reports|June 25, 2013
Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk menEmma Killick, Richard Morgan, Francesca Launchbury, et al.
Pageof 20